To this end, multiple ongoing clinical trials (clinical trials: NCT02792465, NCT03568422 and NCT05251714) are now in place to validate the efficacy of small-molecule inhibitors of TTK as an antimitotic therapeutic target for several cancers [92]. This evidence concerns the gene TTK and cancer.